Display Settings:

Format

Send to:

Choose Destination

    Rev Neurol (Paris). 2007 Jan;163(1):38-46.

    [CARIMS (Cancer Risk In Multiple Sclerosis) project: impact of long-term treatment]

    [Article in French]

    Lebrun C, Debouverie M, Vermersch P, Clavelou P, Rumbach L, de Seze J, Defer G, Berthier F; Club Francophone de la Sclérose en Plaques.

    Service de Neurologie, CHU Pasteur, Nice. lebrun.c@chu-nice.fr

    Controversial results have been published on potential link between cancer and multiple sclerosis. Multiple sclerosis has been linked to reduced rates of cancer prior to the era of immunomodulating or immunosuppressive treatments and until today, only 9 studies can be found in the literature. New strategies and early use of IM or IS drugs in MS justify to study and follow patients to detect a potential increase of cancer's incidence in treated patients. It is important to follow and collect prospectively in MS centers, patients with history of cancer, to document histologies, and potential relations with repeated IM or IS treatments. A prospective study is in progress in French MS centers on behalf the Club Francophone de la SEP (CARIMS Project).

    PMID: 17304171 [PubMed - indexed for MEDLINE]

    Supplemental Content

    Click here to read Click here to read

    Patient drug information

    • Cyclophosphamide (Cytoxan®, Neosar®)

      Your doctor has ordered the drug cyclophosphamide to help treat your illness. The drug can be taken by mouth in tablet form or be given by injection into a vein.

    • Methotrexate (Rheumatrex®, Trexall®)

      Methotrexate is used to treat severe psoriasis (a skin disease in which red, scaly patches form on some areas of the body) that cannot be controlled by other treatments. Methotrexate is also used along with rest, physica...